Professor Charles E. Geyer: Neoadjuvant therapy is becoming standard of care for HER2+ breast cancer

Charles E. Geyer

Research output: Contribution to journalEditorial

1 Citation (Scopus)
Original languageEnglish (US)
JournalChinese Clinical Oncology
Volume5
Issue number5
DOIs
StatePublished - 2016

Fingerprint

Neoadjuvant Therapy
Standard of Care
Breast Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Professor Charles E. Geyer : Neoadjuvant therapy is becoming standard of care for HER2+ breast cancer. / Geyer, Charles E.

In: Chinese Clinical Oncology, Vol. 5, No. 5, 2016.

Research output: Contribution to journalEditorial

@article{e299434e8fce458295914eedad72763e,
title = "Professor Charles E. Geyer: Neoadjuvant therapy is becoming standard of care for HER2+ breast cancer",
author = "Geyer, {Charles E.}",
year = "2016",
doi = "10.21037/cco.2016.10.06",
language = "English (US)",
volume = "5",
journal = "Chinese Clinical Oncology",
issn = "2304-3865",
publisher = "Society for Translational Medicine (STM)",
number = "5",

}

TY - JOUR

T1 - Professor Charles E. Geyer

T2 - Neoadjuvant therapy is becoming standard of care for HER2+ breast cancer

AU - Geyer, Charles E.

PY - 2016

Y1 - 2016

UR - http://www.scopus.com/inward/record.url?scp=84998953653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998953653&partnerID=8YFLogxK

U2 - 10.21037/cco.2016.10.06

DO - 10.21037/cco.2016.10.06

M3 - Editorial

C2 - 27829284

AN - SCOPUS:84998953653

VL - 5

JO - Chinese Clinical Oncology

JF - Chinese Clinical Oncology

SN - 2304-3865

IS - 5

ER -